- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02318862
Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
April 27, 2017 updated by: Michael Vaezi, Vanderbilt University Medical Center
Gastroesophageal reflux disease (GERD) is a common condition affecting more than 100 million adults in the U.S., and it significantly impacts patients' quality of life while imposing billions of dollars of direct and indirect costs each year upon our healthcare system.
Current diagnostic tests for GERD are highly invasive and medically inadequate, and the goal of this project is to develop a novel, minimally invasive Mucosal Impedance technique for more accurate detection of GERD while reducing costs.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Vanderbilt University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients undergoing standard of care EGD with 48-hr pH testing by BRAVO
- Previous diagnosis of reflux
- At least 18 years of age
Exclusion Criteria:
- Those less than 18 years of age
- Unable to give informed consent
- Use of acid suppressive therapy within the last 10 days
- Known history of Barrett's esophagus, gastric surgery, alcoholism, or significant motility condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: GERD
Those who have abnormal pH and abnormal esophageal mucosa and those who have abnormal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
|
|
OTHER: non-GERD
Those who have normal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of lower esophageal impedance using mucosal impedance catheter
Time Frame: During standard of care EGD
|
Mucosal impedance is obtained during routine care EGD and readings are compared to 48-hour Bravo capsule results.
Mucosal impedance only takes one minute to perform during endoscopy.
|
During standard of care EGD
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (ACTUAL)
December 1, 2016
Study Completion (ACTUAL)
December 1, 2016
Study Registration Dates
First Submitted
September 4, 2013
First Submitted That Met QC Criteria
December 11, 2014
First Posted (ESTIMATE)
December 17, 2014
Study Record Updates
Last Update Posted (ACTUAL)
May 1, 2017
Last Update Submitted That Met QC Criteria
April 27, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 130084
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux Disease (GERD)
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux Disease (GERD) | RefluxUnited States, Canada
-
Torax Medical IncorporatedCompletedGERD Gastroesophageal Reflux DiseaseUnited States
-
Wake Forest University Health SciencesTakedaCompletedGastroesophageal Reflux Disease (GERD)United States
-
AstraZenecai3 InnovusCompletedGastroesophageal Reflux Disease (GERD)United States
-
NDO Surgical, Inc.TerminatedGastroesophageal Reflux Disease (GERD)United States, Belgium, Germany
-
NDO Surgical, Inc.CompletedGastroesophageal Reflux Disease (GERD)United States, Canada
-
Implantica CE Reflux Ltd.RecruitingGastroesophageal Reflux Disease (GERD)Switzerland, Germany
-
Dexa Medica GroupTerminatedGastroesophageal Reflux Disease (GERD)Indonesia
-
AstraZenecaCompletedGastroesophageal Reflux Disease (GERD)United States, France, Poland, Germany
Clinical Trials on Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedFunctional Dyspepsia | Gastroesophageal Reflux Disease (GERD) | Eosinophilic Esophagitis (EoE)United States
-
Mayo ClinicCompleted
-
Ivashkin Vladimir TrofimovichAbbottCompletedGastroesophageal Reflux Disease (GERD)Russian Federation
-
Duke UniversityCompletedHuman Papilloma Virus Infection | Carcinoma in Situ of Uterine CervixKenya
-
University of ChicagoCompletedGastroesophageal RefluxUnited States
-
University of PennsylvaniaCompletedHypercholesterolemia, Familial
-
University of PennsylvaniaMedical University of South Carolina; NYU Langone Health; National Institute... and other collaboratorsTerminatedHead and Neck Cancer | Oral MucositisUnited States
-
Bionano GenomicsColumbia University; University of Iowa; Medical College of Wisconsin; Augusta... and other collaboratorsRecruitingIntellectual Disability | Autism Spectrum Disorder | Fragile X Syndrome | Developmental Disability | Congenital Anomaly | Facioscapulohumeral Muscular Dystrophy 1United States
-
Kaiser PermanenteUniversity of California, San DiegoCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed